Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAND567 versus placebo in hospitalized patients with COVID-19
2020-002322-85Phase 2Completed
- Sponsor
- Kancera
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) comparing KAND567 with Placebo (2 arms). Primary endpoint: Occurrence of adverse events and serious adverse events. Started May 2020; status: completed.
02
Drugs
rugocrixan
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-002322-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002322-85.